Imperial Innovations Group plc, the quoted technology transfer arm of Imperial College, has published financial results for the year ended 30 July 2010, highlighting the sale of the respiratory specialist Respivert for £9.5 million, an overall 4.7 times return on its three-year investment.
In total the company made £9.9 million from exiting companies, while making new investments of £14 million in 20 companies. This brings to £47.9 million the total investment Imperial Innovations has made...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.